Latest Conference Coverage
Recognizing and Investigating the Prodromal Phase in MS and NMOSD: Dalia Rotstein, MD, MPH
March 2nd 2025The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]
Investigating Immune Cell Signatures in Multiple Sclerosis Progression: Stephanie Zandee, PhD
March 1st 2025At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]
Paving the Way for Autoimmune Neurology Treatment With CAR T-Cell Therapy: Amanda Piquet, MD, FAAN
February 28th 2025The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]
Unraveling Smoldering Multiple Sclerosis and Progressive Disability: Bruce Bebo, PhD
February 27th 2025The executive vice president of research at National MS Society discussed the role of compartmentalized inflammation, microglial interactions, and emerging therapeutic targets in multiple sclerosis. [WATCH TIME: 4 minutes]
Phase 4 Study to Test Switch From Anti-CD20 Therapy to Ozanimod in Stable MS
February 27th 2025The study will track patients over 36 months and use T2 lesion count and the number of serious infections as primary endpoints, with secondary endpoints including adverse events, relapse rates, and the achievement of no evidence of disease activity.
Notable Sessions to Eye Amid the 2025 ACTRIMS Forum: Véronique Miron, PhD
February 25th 2025The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave clinical insights on emerging, innovative tracks at the 2025 ACTRIMS Forum and how these sessions align with recent trends in the multiple sclerosis field. [WATCH TIME: 4 minutes]
Steps in Translating Genetic Discoveries Into Effective Treatments for ALS: Matthew B. Harms, MD
February 24th 2025The associate professor of neurology at Columbia University provided commentary on the rapid advancements in translating genetic research into ALS treatments and the challenges that remain. [WATCH TIME: 5 minutes]
Nuances in Thrombectomy Techniques and Anesthesia Use for Stroke: J Mocco, MD, MS
February 23rd 2025The director of the Cerebrovascular Center at Mount Sinai discussed how results from the ESCAPE-MeVO trial highlight the impact of anesthesia rates, thrombectomy techniques, and the need for rigorous clinical trials to minimize bias. [WATCH TIME: 3 minutes]
Navigating the Future of Gene Therapy in Neuromuscular Disorders: John Brandsema, MD
February 20th 2025The pediatric neurologist at Children’s Hospital of Philadelphia provided background on a notable track session at the upcoming MDA Clinical & Scientific Conference covering updates in gene therapy for neuromuscular conditions. [WATCH TIME: 4 minutes]
Advancing Therapeutic Knowledge of Genetic Influence in ALS: Matthew B. Harms, MD
February 19th 2025The associate professor of neurology at Columbia University gave clinical insight on what neurologists and other neuromuscular specialists can expect from the ALS/frontotemporal dementia track at this year’s MDA Clinical & Scientific Conference. [WATCH TIME: 3 minutes]
ALS, Genetics, and New Horizons: What to Expect at the 2025 MDA Conference
February 18th 2025Matthew B. Harms, MD, an associate professor of neurology at Columbia University Irving Medical Center, an MDA Care Center, gave clinical insights on the advances in ALS genetic research and what clinicians can expect from the ALS/FTD track at the 2025 MDA Clinical & Scientific Conference.
Expanding the Development of Cell Therapy for Muscular Dystrophy: Rita Perlingeiro, PhD
February 18th 2025The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2025 conference. [WATCH TIME: 8 minutes]
Key Considerations When Incorporating Stroke Trial Data Into Clinical Practice: J Mocco, MD, MS
February 17th 2025The director of the Cerebrovascular Center at Mount Sinai highlighted key differences in patient selection criteria and trial designs that may influence how stroke treatment data is applied in clinical practice. [WATCH TIME: 5 minutes]
Advancements in Mechanical Thrombectomy and Imaging: A Stroke Neurologist’s Perspective
February 14th 2025Andrei Alexandrov, MD, chair of the department of neurology at the University of Arizona College of Medicine, covered the latest advancements in stroke care from ISC 2025, from expanding thrombectomy indications to evolving imaging techniques.
